Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

Abstract

Postinfection immunisation of symptom-free HIV-infected patients with MNrgp120 vaccine did not alter HIV-1 disease progression as measured by immunological, virological, and clinical endpoints over a 15-month period.